The global sinusitis treatment market was estimated at US$ 3 bn in 2020 and is expected to hit US$ 4.3 billion by 2030 with at a CAGR of 4.1% from 2021 to 2030.
The global sinusitis treatment market was estimated at US$ 3 bn in 2020 and is expected to hit US$ 4.3 billion by 2030 with at a CAGR of 4.1% from 2021 to 2030.
Sinuses are a connected system of air-filled cavities located in the skull. Sinusitis is an inflammation of the sinus lining caused by bacteria, virus, fungi, and microbes. Bacterial sinusitis is less common than viral sinusitis and requires antibiotics, while viral sinusitis is most common and does not require antibiotics.
Fungal sinusitis is also known as allergic fungal sinusitis and is caused by aspergillosis fungi. Possible symptoms of sinus infection are nasal obstruction, discolored nasal discharge, and facial pain that lasts for seven days or more. Facial pain is a common symptom in sinusitis. A patient could feel pain around the eye, forehead, nose, and root of teeth. There are three primary types of sinusitis: acute sinusitis, sub-acute sinusitis, and chronic sinusitis.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38529
Acute rhinosinusitis is a general disease with global prevalence. The disease is a major burden on health services. Rhinosinusitis is a major health problem globally. It is an infection of the nasal passages and paranasal sinuses.
Primary care physicians usually tend to think of sinusitis as an acute bacterial infection. Hence, antibiotics are prescribed to 92% of patients in the U.K. and 85% to 98% of sinusitis patients in the U.S. In 2003, the number of medical prescriptions for acute bacterial sinusitis was around 7.6 million in Germany. In France, around 7% of all antibiotics are prescribed to treat suspected acute bacterial sinusitis.
The annual cost of treatment in the U.K. is GBP 10 Mn (EUR 14.7 Mn, US$ 20 Mn). In 1996, the total cost of prescription and non‐prescription medications used for the treatment of sinusitis in the U.S. was around US$ 3.39 Bn (EUR 2.5 Bn, GBP 1.7 Bn). Rhinosinusitis accounted for around 12 million to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the growth of the global sinusitis treatment market.
Ask here for more details@ https://www.visionresearchreports.com/report/enquiry/38529
Report Scope
In terms of treatment, the global sinusitis treatment market has been classified into analgesics, antihistamines, corticosteroids, antibiotics, sulphonamides, quinolones, and surgery. Antibiotics have been split into cephalosporin, penicillin, and macrolide. The surgery segment has been bifurcated into endoscopy and balloon sinusplasty. The antihistamines segment accounted for 32% share of the global market in 2020. The segment is anticipated to expand at a CAGR of 3.8% from 2021 to 2030. Antihistamines are over-the-counter medication used to relieve cold, sinus, and allergy symptoms. Hence, increase in usage of these drugs boosts the growth of the segment.
Based on disease type, the global sinusitis treatment market has been categorized into acute sinusitis, sub-acute sinusitis, and chronic sinusitis. The acute sinusitis segment accounted for 35% share of the market in 2020. The segment is expected to expand at a CAGR of 4% from 2021 to 2030. Acute sinusitis is generally caused by common cold. Signs and symptoms could include nasal obstruction and congestion, which may block sinuses in patients and prevent drainage of mucus. Hence, rise in cases of common cold & flu increases the incidence of acute sinusitis. This, in turn, propels the global sinusitis treatment market.
In terms of route of administration, the global sinusitis treatment market has been segregated into topical, nasal, oral, and injectable. The oral segment accounted for 60% share of the global market in 2020. The segment is projected to expand at a CAGR of 3.7% from 2021 to 2030. The oral pathway has attracted the most attention due to unique advantages, including sustained and controllable delivery, feasibility for solid formulations, ease of administration, patient compliance, and an intensified immune response in the case of vaccines.
Based on distribution channel, the global sinusitis treatment market has been divided into online pharmacies, retail pharmacies, and hospital pharmacies. The retail pharmacies segment held 44% share of the market in 2020. The segment is likely to gain market share marginally to reach 44.7% by 2030, as drugs are easily available and various brands are offered at reasonable prices at retail pharmacies.
In terms of region, the global sinusitis treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a significant share of the global market because of higher prevalence of sinusitis. According to the Centers for Disease Control and Prevention (CDC), nearly 26.8 million people were diagnosed with sinusitis in the U.S. in 2019. Europe is anticipated to be a key market for sinusitis treatment due to rise in invasive bacterial diseases and innovation in diagnosis of bacterial infections.
The sinusitis treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to increase in bacterial and viral diseases. However, factors, such as lack of knowledge of diagnostic tests and awareness among people about sinusitis is likely to hamper the growth of the market in the region.
Competitive Landscape and Market Share Analysis
The sinusitis treatment market competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, sinusitis treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2017-2020, this study provides the sinusitis treatment sales, revenue and market share for each player covered in this report.
- Crucial data regarding the major contenders, product portfolio, market remuneration, and production patterns are documented in the report.
- The report presents the pricing models followed by each company, alongside the gross margins and market share held by each company.
The global sinusitis treatment market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy’s Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc., Aurobindo Pharma, Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V.
Global Sinusitis Treatment Market: Segmentation
Sinusitis Treatment Market, By Treatment
-
- Antihistamines
- Analgesics
- Corticosteroids
- Antibiotics
- Cephalosporin
- Penicillin
- Macrolide
- Sulphonamides
- Quinolones
- Surgery
- Endoscopy
- Balloon Sinusplasty
Sinusitis Treatment Market, By Disease Type
-
- Acute Sinusitis
- Sub-acute Sinusitis
- Chronic Sinusitis
Sinusitis Treatment Market, By Route of Administration
-
- Topical
- Nasal
- Oral
- Injectable
Sinusitis Treatment Market, By Distribution Channel
-
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Sinusitis Treatment Market, By Region
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38529
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333